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Functional modulation of the mineralocorticoid receptor by mas [4]. cDDP-induced nephrotoxicity is recognized as
cis-diamminedichloroplatinum (II). an important dose-limiting factor, which is characterized
Background. Renal salt wasting and hypotension are some either as acute renal failure or renal electrolyte wasting,of the frequent complications in patients treated with cis-diam-
such as magnesium, calcium, and sodium [5–8]. It hasminedichloroplatinum (II) (cDDP), and it is suggested that
been reported that the renal sodium wasting manifestedcDDP produces an abnormality in the renin-angiotensin sys-
tem. However, not only the underlying mechanism but also with polyuria, hyponatremia, and significant volume
prophylactic treatment of this cDDP toxicity remains unknown. depletion is developed in approximately 10% of patients
In the present study, we investigated the molecular mechanism treated with cDDP. This disorder could be cured afterof this cDDP-induced disturbance of renal sodium handling
the administration of mineralocorticoid and supplemen-with focusing on the effect of cDDP on mineralocorticoid re-
tal sodium, suggesting that an abnormality of mineralo-ceptor (MR) function.
Methods. The effect of cDDP was studied on nuclear trans- corticoid secretion and/or renal responsiveness to mineral-
location, DNA binding activity, and transactivation function ocorticoid may play a major role in this process [8].
of the MR. Recent studies have shown that reactive oxygen speciesResults. In a transient transfection assay, cDDP suppressed
(ROS) are closely associated with renal injury inducedMR-dependent reporter gene expression. This cDDP-medi-
by, for example, ischemia/reperfusion [9–12] and vari-ated repression of MR function, at least in part, is suggested
to be due to the generation of reactive oxygen species and a able nephrotoxins [13–15]. On the other hand, cDDP,
subsequent decrease in ligand-dependent nuclear translocation along with other anticancer drugs, is known to generate
and suppression of the interaction with DNA of the MR. This ROS in cells [16], and the administration of free radicalredox-dependent repression of MR function both in vitro and
scavengers or antioxidants is preliminarily reported toin vivo was reversed by treatment with reducing reagents.
protect against cDDP-induced nephrotoxicity in animalMoreover, cDDP, most possibly via formation of DNA ad-
ducts, inhibited MR–DNA interaction in a redox-independent models and humans [17]. ROS therefore seems to play a
fashion. critical role in cDDP-induced nephrotoxicity [16]. How-
Conclusions. MR function is impaired by cDDP at multiple ever, the precise molecular mechanism of cDDP-inducedlevels, via redox-dependent and -independent mechanisms.
renal sodium wasting remains unknown.
Sodium homeostasis is mainly maintained by adrenal
aldosterone via binding to the mineralocorticoid recep-
Cis-diamminedichloroplatinum (II) (cDDP) induces
tor (MR), which is expressed in epithelial cells of the
cytotoxicity by DNA adduct formation [1], peroxidation
renal tubules, colon, and salivary gland [18]. Indeed,
of the cell membrane [2], and mitochondrial dysfunction
Berger et al generated MR knockout mice and confirmed[3], and has been widely used as a potent anticancer drug
that the MR is indispensable for sodium homeostasisto treat solid tumors, including testicular, head and neck,
and maintenance of extracellular volume [19]. The MRovarian, bladder, esophagus, and uterine cervix carcino-
is a ligand-dependent transcription factor that, as well as
the glucocorticoid receptor (GR), belongs to the nuclear
receptor superfamily, which is comprised of distinct do-Key words: cisplatin, transcription, renin-angiotensin system, kidney
toxicity, sodium handling, anticancer drug. mains for DNA binding, ligand binding, and transactiva-
tion function [20]. After ligand binding, the MR dissoci-Received for publication February 22, 2000
ates from heat shock proteins (hsps) and translocatesand in revised form May 3, 2000
Accepted for publication May 12, 2000 into the nucleus to regulate target gene expression [21].
Although target genes of the MR have not been wellÓ 2000 by the International Society of Nephrology
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characterized, the MR can bind to the glucocorticoid Cell culture
response element (GRE) in vitro with high affinity as COS7 cells were obtained from RIKEN Cell Bank
well as the GR [22]. GRE sequences have been found (Tsukuba Science City, Japan) and maintained in phenol
in the promoter regions of aldosterone-responsive endog- red-free Dulbecco’s modified Eagle’s medium (DMEM;
enous genes (for example, Na1,K1-ATPase gene) and Iwaki Glass Inc., Chiba Japan), pH 7.0, supplemented
have been shown to be essential for aldosterone-inducible with 10% heat-inactivated fetal calf serum (Life Tech-
gene expression [23]. Correspondingly, the DNA binding nologies, Inc., Rockville, MD, USA) and antibiotics. In
domain (DBD) of the MR is highly homologous with all experiments, serum was stripped with dextran-coated
charcoal, and cells were cultured in a humidified atmo-that of the GR [20]. Accordingly, the GRE is considered
sphere at 378C with 5% CO2.to function as a mineralocorticoid response element
(MRE) as well. Growing evidence has indicated that the
Measurement of reactive oxygen species productionGR function can be modulated not only by ligand, but
Intracellular generation of ROS in cDDP or H2O2-also via a variety of cellular signals and extracellular
treated COS7 cells was monitored by flow cytometricstimuli, including the cellular oxido-reductive (redox)
analysis with DCFH-DA, which is a nonfluorescent andstate [24–28]. However, very little is known about the
nonpolar compound that diffuses through the cell mem-conditional regulation of the MR.
brane. Within the cell, it is converted into a nonfluores-In the present study, we showed that cDDP suppresses
cent polar product DCFH by endogenous esterases andMR-dependent transcription. This inhibition, at least in
can no longer pass out of the cell. DCFH is rapidlypart, may be due to functional impairment of the MR
oxidized to fluorescent compound 29,79-dichlorofluor-caused by generation of ROS and possible formation of
escein (DCF) in the presence of ROS. In brief, COS7DNA adducts.
cells were incubated in the presence of cDDP for six
hours or in the presence of H2O2 for two hours, and
the medium was replaced with freshly prepared DMEMMETHODS
containing 10 mmol/L DCFH-DA. After an additionalReagents and antibodies
incubation for 30 minutes at 378C, the cells were washed
Cis-diamminedichloroplatinum, dexamethasone, aldo- twice with ice-cold phosphate-buffered saline (PBS),
sterone, diamide, 2-mercaptoethanol (2ME), and N-acetyl- then detached with trypsin and ethylenediaminetetraace-
L-cysteine (NAC) were purchased from Sigma Chemical tic acid (EDTA), and again washed twice with ice-cold
Co. (St. Louis, MO, USA). 29,79-dichlorofluorescein di- PBS. The cells were finally suspended in an appropriate
acetate (DCFH-DA) was from Molecular Probes, Inc. volume of PBS and analyzed using Coulter Elite (Coul-
(Eugene, OR, USA). Other chemicals were from Wako ter, Miami, FL, USA) with an excitation wavelength of
Pure Chemical (Osaka, Japan) unless otherwise speci- 480 nm and an emission wavelength of 525 nm (30,000
fied. Anti-polyclonal GFP antibody was purchased from live cells were analyzed per sample).
Clontech Laboratories (Palo Alto, CA, USA), and anti-
Transfection and luciferase assayMR and anti-VP16 polyclonal antibodies were from
Transient transfection was performed as describedSanta Cruz (Santa Cruz, CA, USA).
previously [24]. Briefly, cells were plated on plastic cul-
Plasmids ture dishes (IWAKI Glass) to 30 to 50% confluence and
were washed with PBS three times, and medium wasThe expression vectors for the MR, pRShMR, were
replaced with phenol red-free Opti-MEM medium (Lifekindly gifted by Dr. R.M. Evans (Salk Institute, La Jolla,
Technologies, Inc.). A plasmid cocktail was mixed withCA, USA). The expression vectors for the chimeric pro-
TransIT-LT1 transfection reagent (Pan Vera Corp., Madi-tein of human MR and GFP, pCMX-hMR-GFP, was
son, WI, USA) and added to the culture. The total amount
kindly supplied Dr. H. Ogawa (Kyoto University, Kyoto,
of the plasmids was kept constant by adding irrelevant
Japan). To construct an expression plasmid for the fusion plasmid (pGEM3Z was used unless otherwise specified).
protein of the VP16 transactivation domain and DBD of After six hours of incubation, the medium was replaced
the human MR, the DNA fragments encoding 103 amino with fresh DMEM supplemented with 2% dextran-coated,
acids (serine 585 to glutamine 688) of the human MR were charcoal-stripped fetal calf serum, and the cells were
amplified by polymerase chain reaction with appropriate further cultured in the absence or presence of various
flanking sequences for enzymatic cleavage and inserted amounts of reagents for 18 hours at 378C. After normal-
into the XbaI and BamHI site of the parent pCMX- ization of the transfection efficiency by b-galactosidase
VP16 [29], resulting in pCMX-VP16-hMR DBD. The expression, luciferase enzyme activity was determined
mineralocorticoid-responsive reporter plasmid pGRE- in a luminometer (Berthold GmbH & Co. KG, Bad Wild-
bad, Germany) essentially as described previously [25].Luc has been described elsewhere [25].
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Visualization of intracellular distribution of Preparation of nuclear extract
hMR-GFP in living cells Nuclear extracts of COS7 cells were prepared by using
For analysis of intracellular distribution of the MR in a nonionic detergent method according to Dignam, Leb-
living cells, we transiently expressed GFP-tagged human ovitz, and Roeder [32]. Briefly, COS7 cells were trans-
MR (hMR-GFP). Briefly, COS7 cells were cultured in fected with pCMX-hMR-GFP and cultured for 24 hours
6 cm diameter collagen-coated plastic dishes. The medium at 378C to afford sufficient synthesis of hMR-GFP, and
was replaced with phenol red-free Opti-MEM medium were incubated with 10 nmol/L aldosterone for two hours
before transfection, and 6 mg of expression plasmid for at 378C, and then detached with trypsin and EDTA. The
the chimeric protein of GFP and human MR pCMX- cells were washed and resuspended in Dignam’s buffer
hMR-GFP were mixed with 12 mL of TransIT-LT1 reagent A containing 0.15% Nonidet P-40 and left for 10 minutes
and added to the culture. After six hours of incubation, on ice and subsequently centrifuged at 1000 3 g for 45
the medium was replaced with DMEM supplemented minutes at 48C. The pellet was treated with Dignam’s
with 2% dextran-coated charcoal-stripped fetal calf se- buffer C for 10 minutes to yield the nuclear extracts.
rum, and the cells were cultured for another 24 hours at Protein concentration was determined by a BCA Protein
378C. GFP protein was expressed at detectable levels Assay Kit (Pierce, Rockford, IL, USA) according to the
between 24 and 72 hours after transfection. After various manufacturer’s protocol.
treatments, hMR-GFP–expressing cells were examined
Electrophoretic mobility shift assayusing a Zeiss Axiovert 135 microscope equipped with a
fluorescein isothiocyanate filter set (FITC, Carl Zeiss, Electrophoretic mobility shift assay (EMSA) was car-
Jena, Germany) [30]. Quantitative assessment of the sub- ried out as described previously [24]. Briefly, double-
cellular localization of expressed hMR-GFP was per- stranded oligonucleotide probes encompassing the MRE/
formed according to methods described by Okamoto et GRE were end labeled with [a-32P]dCTP (Amersham,
al [27]. In brief, subcellular localization analysis of hMR- Buckinghamshire, UK) using the Klenow fragment of
GFP was performed by blinded observers, counting ap- DNA polymerase I (TaKaRa, Kyoto, Japan). Nuclear
proximately 200 cells in which GFP fluorescence was extracts (10 mg of protein per reaction) containing hMR-
detected. The GFP-fluorescence–positive cells were clas- GFP protein were incubated on ice for 15 minutes in a
sified into four different categories: (1) N , C for cyto- 20 mL reaction mixture containing 10 mmol/L of Tris-
plasmic dominant fluorescence; (2) N 5 C, cells having HCl (pH 7.5), 80 mmol/L KCl, 1 mmol/L dithiothreitol,
equal distribution of fluorescence in the cytoplasmic and 250 ng poly(dI-dC) (Amersham Pharmacia Biotech, Upp-
nuclear compartments; (3) N . C for nuclear dominant sala, Sweden), 10% glycerol, and 0.2 ng of 32P-labeled
fluorescence; and (4) N for exclusive nuclear fluorescence. MRE/GRE oligonucleotide probes (approximately 30,000
cpm/reaction). For the supershift assay, an anti-hMRImmunocytochemical analysis
polyclonal antibody MCR C-19, recognizing an amino
COS7 cells grown on silane-coated cover slips were acid sequence mapping at the carboxy terminus of the
transiently transfected with the expression plasmid for MR of human origin (Santa Cruz) or an anti-GFP poly-
the fusion protein of VP16 transactivation domain and
clonal antibody (Clontech) was included in the reaction
the DBD of the human MR, VP16-hMR DBD. Cells
mixture. The reaction mixture was loaded onto 4% poly-were then fixed for immunostaining using a freshly pre-
acrylamide gel containing 0.25 3 Tris/borate/EDTA solu-pared solution of 4% paraformaldehyde (wt/vol) in PBS
tion (1x 5 89 mmol/L Tris-borate, and 2 mmol/L EDTA).overnight at 48C. Immunocytochemistry was carried out
The gels were run at 350 V for two hours and thenas described previously [31]. Briefly, after fixation, cells
dried. Results were visualized by autoradiography. Thewere washed five times with PBS at room temperature
sequences of the oligonucleotides encompassing MRE/and incubated with anti-VP16 polyclonal goat antibody
GRE is 59-CGAGTAGCTAGAACAGACTGTTCTGat 2 mg/mL in PBS containing 0.1% Triton X-100 for
AGG-39 (upper strand is shown).nine hours at 48C. The cells were then washed further
five times with PBS and incubated with biotinylated anti-
goat IgG antibody at a dilution of 1:200 in PBS containing RESULTS
0.1% Triton X-100 for one hour at room temperature and
Oxidative conditions inhibit ligand-dependentwashed five times with PBS and incubated with FITC-
transactivational function of the MRconjugated streptavidin at a dilution of 1:100 in PBS
In analogy with the case of the GR (discussed previ-containing 0.1% Triton X-100 for one hour at room
ously in this article), we speculated that MR function istemperature. The cells were then washed five times with
also regulated in a redox-dependent manner. To assessPBS, and the cover slips were mounted on glass slides
whether oxidative treatment affects ligand-dependentfor examination on a Zeiss Axiovert 135 microscope
equipped with a FITC filter set. transactivational function of the MR, we transfected MR
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Fig. 1. Redox regulation of the transactivation function of the mineral-
ocorticoid receptor (MR). COS7 cells were transfected with 1 mg of
the mineralocorticoid-inducible reporter plasmid pGRE-Luc (lanes 1
through 7) and 100 ng of MR expression plasmid pRShMR (lanes 3
through 7) and were cultured for 18 hours in the absence or presence
of 1 mmol/L H2O2 (lanes 5 through 7), 1 or 10 mmol/L of NAC, and
10 nmol/L aldosterone (Ald) as indicated. Cellular luciferase activity
was determined as described in the Methods section. Results are ex-
pressed as relative light unit (RLU) per microgram protein. Fig. 2. Effect of cis-diamminedichloroplatinum (cDDP) and H2O2 on
generation of reactive oxygen species (ROS) in COS7 cells. COS7 cells
were cultured for six hours in the absence (A) or presence (B) of
25 mmol/L cDDP, or for two hours in the presence of H2O2 (C), and
the culture medium was replaced with the freshly prepared medium
expression plasmid pRShMR and aldosterone-respon- containing 10 mmol/L DCFH-DA. After 30 minutes of incubation, fluo-
rescence intensity was measured by flow cytometry as described in thesive reporter plasmid pGRE-Luc into COS7 cells. After
Methods section.treatment with 10 nmol/L aldosterone, expression of the
reporter gene was induced by 15-fold (Fig. 1, compare
lanes 1 and 4). However, in the presence of 1 mmol/L
H2O2, this aldosterone-dependent transcriptional induc- shown in Figure 3, cDDP repressed the transactivational
tion was significantly reduced (compare lanes 4 and 5), function of the MR in a concentration-dependent man-
and the repression effect was countered by NAC in a ner (lanes 4 through 8). In clear contrast to the case of
concentration-dependent manner (lanes 5 to 7). repression by H2O2, restoration of MR transactivational
function by 10 mmol/L NAC was not complete in cDDP-
cDDP generates ROS in COS7 cells treated cells (lane 9, compare with lane 4), indicating the
To test whether treatment with cDDP generates ROS, presence of not only redox-mediated but also redox-inde-
COS7 cells were cultured in the presence of 25 mmol/L pendent mechanisms for cDDP inhibition of MR function.
cDDP or 1 mmol/L H2O2 and loaded with DCFH-DA
Effects of cDDP on subcellular localization of the MRfor 30 minutes, and then ROS production was assayed
as described in the Methods section. As shown in Figure To examine an underlying mechanism of the cDDP-
2, the intracellular fluorescence intensity of DCF was dependent inhibition of the transactivational function of
increased in cDDP-treated cells as well as in H2O2- the MR, we first investigated the effect of cDDP on
treated cells, suggesting that treatment with cDDP en- subcellular localization of the MR. For this purpose, we
hances production of intracellular ROS. monitored the intracellular localization of a chimeric
protein of GFP and MR, hMR-GFP, in living COS7 cells.
Suppression of transactivational function of the As shown in Figure 4A, transiently expressed hMR-GFP
MR by cDDP docked in the cytoplasm in the absence of ligand and
Given the previous results, we speculated that cDDP translocated into the nucleus in the presence of 10
decreases aldosterone-dependent gene expression, most nmol/L aldosterone. Since hMR-GFP activated expres-
possibly via generation of ROS. After transfection of sion of the reporter gene in a ligand-dependent manner
MR expression plasmid and the aldosterone-responsive the same way as wild-type receptor (Fig. 4B), we con-
reporter plasmid, COS7 cells were cultured in the ab- cluded that this chimeric protein, at least functionally,
mimics wild-type MR. Moreover, transcriptional repres-sence or presence of aldosterone, cDDP, and NAC. As
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Fig. 3. Effect of treatment with cDDP on the transactivational function
of the MR. COS7 cells were transfected with 1 mg of the mineralocorti-
coid-inducible reporter plasmid pGRE-Luc (lanes 1 through 9) and
100 ng of MR expression plasmid pRShMR (lanes 3 through 9) and were
cultured for 18 hours in the presence of the indicated concentrations of
cDDP, 10 mmol/L NAC, and 10 nmol/L aldosterone (Ald). Cellular
luciferase activity was determined as described in the Methods section.
Results are expressed as relative light unit (RLU) per microgram pro-
tein.
Fig. 4. Human mineralocorticoid receptor tagged with green fluores-
cent protein (hMR-GFP) mimics wild-type mineralocorticoid receptor
(MR). (A) COS7 cells were transfected with the expression plasmid
for the chimeric protein of GFP and the human MR pCMX-hMR-sion effects of cDDP and H2O2 were also similarly ob- GFP. The cells were cultured in the absence or presence of 10 nmol/L
served, and restoration by treatment with 10 mmol/L aldosterone for two hours, and then photographs were taken as de-
scribed in the Methods section. (B) COS7 cells were transfected withNAC was incomplete when treated by cDDP (Fig. 4B).
1 mg of the reporter plasmid pGRE-Luc and 100 ng pCMX-hMR-GFPWe then examined the effect of oxidative stress on
and were then cultured for 18 hours in the presence of aldosterone,
ligand-dependent nuclear translocation of hMR-GFP in cDDP, H2O2, and NAC as indicated. Cellular luciferase activity was
determined as described in the Methods section. Results are expressedCOS7 cells. As shown in Figure 5B, the rate of ligand-
as relative light unit (RLU) per microgram protein.dependent nuclear translocation of hMR-GFP was de-
creased in the presence of 1 mmol/L H2O2. This sup-
pressive effect of H2O2 was completely rescued by NAC,
as previously reported in the case of the GR by us [27], Expressed VP16-hMRDBD constitutively localized in
suggesting that the ligand-dependent nuclear transloca- the nucleus either in the absence or presence of either
tion of the MR is regulated by cellular redox state as well H2O2 or cDDP (data not shown; Fig. 6A). After transfec-
as that of the GR. We next examined the effect of cDDP tion of pCMX-VP16-hMRDBD with the reporter plas-
on ligand-dependent translocation of hMR-GFP. As mid pGRE-Luc, COS7 cells were cultured in the absence
shown in Figure 5C, in the presence of cDDP, the delay or presence of H2O2, cDDP, and NAC, as indicated in the
of ligand-dependent nuclear translocation of hMR-GFP legend for Figure 6B. In the absence of VP16-hMRDBD,
was not so provocative, but again, only partially restored basal level expression of the reporter gene was low, and
by NAC. effect of treatment with cDDP or H2O2 was not signifi-
cant (Fig. 6B). In the presence of VP16-hMRDBD, ex-
Effects of cDDP on the DNA binding of the pression of the reporter gene was activated even in the
MR in situ absence of ligand, indicating that this chimeric protein
We previously demonstrated that several functions of constitutively binds to MRE/GRE in the nucleus. Treat-
the GR, including DNA binding, are independently sus- ment with either H2O2 or cDDP suppressed expression of
ceptible to oxidative treatment [24–28]. Since the DBD is the reporter gene by several-fold, and NAC significantly
extremely conserved between the MR and GR, we then squelched these negative effects of cDDP (Fig. 6B). Note
tested the effect of H2O2 and cDDP on the interaction that, as described previously, the rescue effect of NAC
between the DBD of the MR and target DNA sequences was again partial when cells were treated with cDDP
in situ, using a one-hybrid assay. For this purpose, we con- (Fig. 6B). We therefore strongly suggest that cDDP in-
structed the plasmid encoding the VP16 transactivation hibits the intranuclear interaction between the DBD of
the MR and target DNA sequences. Moreover, the factdomain and the MR DBD in frame, VP16-hMRDBD.
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Fig. 5. Effect of treatment with H2O2 cDDP
on subcellular localization of hMR-GFP. (A)
Classification of the subcellular localization of
hMR-GFP is: N , C for cytoplasmic domi-
nant; N 5 C for having equal distribution in
the cytoplasmic and nuclear compartments;
N . C for nuclear dominant; N for exclusive
nuclear localization. (B) Effect of H2O2. COS7
cells were transfected with 6 mg of pCMX-
hMR-GFP, and hMR-GFP–expressing cells
were incubated for two hours in the absence
(h) or presence of 1 mmol/L H2O2 (d) or 1
mmol/L H2O2 and 5 mmol/L NAC (s), and
then 10 nmol/L of aldosterone (final concen-
trations) were added. (C) Effect of cDDP.
hMR-GFP–expressing cells were incubated
for six hours in the absence (h) or presence
of 25 mmol/L cDDP (d) or 25 mmol/L cDDP
and 5 mmol/L NAC (s), and then 10 nmol/L
aldosterone (final concentrations) were added.
At the indicated time points after the addition
of aldosterone, the subcellular localization of
hMR-GFP was quantitatively assessed, and the
percentages of the category N of total fluores-
cence-positive cells are shown. Experiments
were repeated twice with almost identical re-
sults, and representative results are shown.
that the restoration of reporter gene expression was in- contrast, formation of lower protein-DNA complexes
was not affected by any treatment and considered non-complete even in the presence of NAC indicates that
not only redox-mediated, but also redox-independent specific. To test the effect of oxidative conditions on MR
DNA binding, we added the increasing concentrationsmechanisms play roles in the inhibition of interaction
between the DBD of the MR and DNA in situ. of an oxidative reagent diamide in the reaction mixtures.
Diamide inhibited sequence-specific DNA binding of
Effect of oxidative treatment and cDDP on hMR-GFP in a concentration-dependent manner (lanes
DNA binding activity of the MR in vitro 5 through 8), and this negative effect of diamide was
completely restored by 2ME (lanes 9 through 11). To-To examine the underlying mechanism of cDDP-
gether, we concluded that DNA binding activity of thedependent inhibition of DNA binding activity of the
MR is regulated in a redox-dependent manner.MR, we performed an EMSA. COS7 cells were trans-
It has been shown that cDDP forms DNA adductsfected with the human MR expression plasmid CMX-
when DNA sequences contain guanine and adenine [33].hMR-GFP. After incubation with 10 nmol/L aldosterone
If such is the case for the MRE sequence, DNA bindingfor two hours, nuclear extracts were prepared and used
of the MR might be suppressed, at least in part, in ain EMSA as a source of the MR. After incubation with
redox-independent manner. To test this possibility, weMRE/GRE oligonucleotide probe DNA and the nuclear
first treated MRE/GRE probe oligonucleotide with cDDPextracts, the samples were fractionated in a native poly-
and did EMSA. Figure 8A shows that treatment of theacrylamide gel, and formation of protein-DNA com-
probe with cDDP had critical effects on the interactionplexes was analyzed. As shown in Figure 7, formation
between hMR-GFP and the probe DNA (lanes 1 throughof upper protein-DNA complexes between the probe
3). Moreover, the addition of 2ME did not restore thisand the cell lysates was not abolished by excess amount
of nonlabeled nonspecific DNA (lanes 1 and 4), but negative effect of cDDP (lanes 4 and 5). Next, we treated
the competitor oligonucleotides with cDDP and per-efficiently abolished by nonlabeled MRE/GRE probe
DNA (lanes 1 through 3), suggesting that the upper bands formed an EMSA. As shown in Figure 8B, nontreated
MRE/GRE oligonucleotides interfered with formationrepresent a specific interaction between the hMR-GFP
and MRE/GRE sequences. This is further supported by of specific protein-DNA complexes between hMR-GFP
and the probe (lanes 1 through 3); however, MRE/GREthe fact that the addition of antibodies against either
GFP or MR clearly supershifted the positions of the oligonucleotides pretreated with cDDP either in the
presence or absence of 2ME did not (lanes 4 and 5).specific protein-DNA complexes (lanes 12 and 13). In
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Fig. 6. Effect of cDDP on the interaction be-
tween the DNA binding domain (DBD) of
the MR and MRE/GRE in situ. (A) The sub-
cellular localization of VP16-MR DBD. COS7
cells were transiently transfected with pCMX-
VP16 MR DBD and subcellular localization
of VP16-MRDBD was immunocytochemi-
cally analyzed as described in the Methods
section. (B) Effect of H2O2 and cDDP. COS7
cells were transfected with 1 mg of the mineral-
ocorticoid-inducible reporter plasmid pGRE-
Luc and 100 ng of pCMX-VP16 MR DBD,
and then the cells were incubated in the pres-
ence of 0.5 or 1 mmol/L H2O2, 5 or 25 mmol/L
cDDP, and 5 mmol/L NAC as indicated. Cel-
lular luciferase activity was determined as de-
scribed in the Methods section. Results are
expressed as percentage of control (lane 4).
We thus conclude that cDDP suppresses MR-dependent essary for ligand binding to the MR [34]. Recently, it
also has been revealed that cysteine 849 and 942 of thegene expression via reversible redox-dependent mecha-
hMR are crucial for steroid binding [35]. Given thesenisms and redox-independent and irreversible modifica-
results, it is likely that ligand binding and subsequenttion of target DNA sequences.
release of hsp90 are inhibited under oxidative conditions,
as in the case of the GR [27]. Considering that nuclear
DISCUSSION translocation is the subsequent event of these processes,
This study demonstrates that MR function is nega- our results may support this idea: Ligand-dependent nu-
tively modulated at multiple levels by cDDP, most possi- clear translocation of the MR is repressed under oxida-
bly via redox-dependent mechanisms and DNA adduct tive conditions and is restored when reducing reagents
formation. are added. As previously described [27], the N-terminal
The MR contains a number of cysteine residues, parts nuclear localization signal (NLS) of the nuclear receptor
of which have been shown to be important for distinct is bipartite and extremely conserved, and almost all nu-
functions of the receptor: ligand binding and DNA bind- clear receptors contain a cysteine residue in the N-termi-
ing. The ligand binding domain (LBD) of the hMR con- nal portion of the NLS. In the case of the GR, we showed
tains four cysteine residues at positions 808, 849, 910, that NL1 functions as a ligand-independent NLS and is
and 942 [20]. It has been reported that MR function is suppressed under oxidative conditions, since mutation
negatively modulated with methylmethane thiosulfo- of the very cysteine to serine makes NL1 resistant to
nate, a reversible cysteine-specific modifying reagent, oxidative treatment [27]. In contrast, the chimeric pro-
tein VP16-hMR DBD constitutively localized in the nu-suggesting that the integrity of the cysteine thiols is nec-
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Fig. 7. Redox regulation of the DNA-bind-
ing activity of the MR in vitro. COS7 cells were
transfected with the hMR expression plasmid
pCMX-hMR-GFP. After incubation with 10
nmol/L aldosterone for two hours, nuclear ex-
tracts were prepared. Ten micrograms of the
nuclear extracts containing hMR-GFP were
incubated with 32P-labeled MRE/GRE-oligo-
nucleotide probe in the absence (lane 1) or
presence (lanes 2 and 3) of a molar excess
of radioinert-specific competitor DNA (MRE/
GRE) and a 20-fold molar excess of nonspe-
cific competitor DNA [hypoxia-response ele-
ment (HRE), lane 4]. When indicated, a thiol-
oxidizing reagent diamide (lanes 5 through 11)
and 2ME (lanes 9 through 11) were added. For
the supershift assay, antibodies raised against
GFP (lane 12) or hMR (lane 13) were added.
Formation of protein-DNA complexes was
visualized by autoradiography as described in
the Methods section. Closed triangle depicts
positions of the specific protein-DNA com-
plexes. Lane F is for free probe.
cleus even in the presence of H2O2. At this moment, we DNA binding as well. The transactivational function of
the chimeric protein of isolated hMR-DBD and the het-do not know the mechanism for this difference in sen-
sitivity to oxidative treatment between the GR and MR. erologous transactivation domain of VP16 (VP16-hMR
DBD) was shown to be markedly repressed by cDDP,cDDP-dependent delay in the ligand-dependent MR
translocation is not completely rescued by treatment with and these effects were partially recovered by NAC. Since
the transactivation domain of VP16 does not containNAC, suggesting a contribution of the redox-indepen-
dent action of cDDP, for example, to the inhibition of cysteine residues, these repression effects may be as-
cribed not only to oxidative modification of hMR DBDhsp90’s function. Indeed, Itoh et al showed that cDDP
binds to hsp90 and induces an aberrant conformation of by cDDP-generated ROS, but also to other mechanisms.
This hypothesis is confirmed by the results from EMSAhsp90 and then inhibits its chaperone activity in vitro
[36]. Because hsp90 is essential for hormone binding and using hMR-GFP. As shown in Figure 7, redox regulation
of DNA binding activity of the MR is reversible. Inits dissociation is a prerequisite for subsequent nuclear
translocation of steroid receptors, including the GR and contrast, cDDP-dependent repression of DNA binding
activity of the MR is suggested to be independent, atMR, our results indicate that cDDP irreversibly affects
hsp90 function in vivo. Of course, further biochemical least in part, from redox regulation (Fig. 8). Numerous
studies have demonstrated that cDDP treatment mayanalysis should be performed to clarify this issue.
We have demonstrated that treatment with cDDP neg- influence the expression of a number of genes, either
positively or negatively via the formation of DNA ad-atively modifies MR function at the level of the receptor-
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enine-guanine sequence that can raise the A^G crosslink
[33], the cDDP-dependent decrease in DNA binding of
the MR may be due to DNA adduct formation. Among
target genes of the MR, for example, growing evidence
shows that the genes for amiloride-sensitive epithelial
sodium channel (ENaC) and Na1,K1-ATPase are posi-
tively regulated by aldosterone and play an important
role in sodium homeostasis [42–46]. The promoter re-
gions of both of these genes contain MRE/GRE, which
has sufficient activity for MR- and/or GR-inducible tran-
scription [42, 43, 46]. Repression of ENaC and Na1,K1-
ATPase gene transcription thus might occur in the pres-
ence of cDDP, most possibly via DNA adduct formation
in MRE/GRE. When cDDP is administered after a sin-
gle-dose injection at therapeutic doses, the plasma level
of cDDP is approximately 10 mmol/L [47], and prolonged
treatment accumulates cDDP, for example, in the kidney
[48, 49]. Furthermore, it is confirmed that cDDP gener-
ates ROS when administered at low doses [16] and raises
the formation of DNA adducts in vivo [50–53]. Along this
line, we speculate that MR-dependent gene expression
could be repressed through ROS generation and DNA
adduct formation in the kidney of patients treated with
cDDP as well. As described previously in this article,
abnormalities in the renin-aldosterone system have been
reported in some patients with cDDP [8, 54, 55]. Hutchi-
son et al described variable abnormalities in plasma renin
activity and serum aldosterone concentration in patients
treated with cDDP, with an emphasis on hypoaldoste-
ronism as a possible cause of hyponatremia and hypoten-
sion [8]. In clear contrast, Bosl et al [54] and Kurt et al
[55] have reported the elevation of plasma renin activity
and serum aldosterone in patients treated with cDDP,
which could be compensation for suppression of the MR
function by cDDP. In any case, there may be more than
Fig. 8. Effect of treatment with cDDP on the DNA-binding activity one underlying mechanisms for the abnormality in the
of the MR in vitro. (A) Effect of pretreatment of the probe DNA with renin-aldosterone system, and further studies are clearlycDDP. 32P-labeled MRE/GRE-oligonucleotide probe was treated with
necessary. Interestingly, it has been reported that cDDP50 mmol/L cDDP for 6 or 24 hours (lanes 2 through 5), and then the
nuclear extracts containing hMR-GFP were incubated. When indicated, represses Na1,K1-ATPase activity and this suppression
5 or 20 mmol/L 2ME (lanes 4 and 5) were added. (B) Effect of pretreat- is restored by 2ME [56]. On the other hand, previousment of the competitor DNA with cDDP. Radioinert competitor MRE/
studies demonstrated that cDDP-DNA adducts inhibitGRE-oligonucleotide was pretreated with 25 mmol/L cDDP for 24 hours
(lanes 4 and 5) in the absence (lane 4) or presence (lane 5) of 20 mmol/L the access of certain transcription factors such as NF-1
2ME and was then added to the incubation mixture containing hMR- and TATA binding proteins to the promoter DNAGFP-rich nuclear extracts and 32P-labeled MRE/GRE-oligonucleotide
[57–61]. The mechanism of cDDP for modulation of geneprobe. When indicated, molar excess of the nontreated (lanes 2 and 3)
radioinert MRE/GRE or nonspecific (lane 6) competitor DNA was expression therefore could be multiple and dependent
added to the incubation mixture. Anti-MR Ab (lane 7) represents a on transcription factors and promoter context.specific antibody for hMR. The triangle depicts the position of specific
It has been shown that other antitumor drugs such asprotein-DNA complexes formed.
adriamycin and mitomycin C also generate ROS. Re-
cently, Zeman, Phillips, and Crothers reported that
adriamycin forms covalent adducts with DNA [62]. Cor-
ducts [37–41]. In the present study, we showed that pre- respondingly, defective renal salt handling has been re-
treatment of MRE/GRE oligonucleotides with cDDP ported in a patient treated with high-dose cDDP, etopo-
reduced MR binding even in the presence of reducing side, and mitomycin C [63]. Therefore, it should be noted
reagents (Fig. 8). Since MER/GRE consensus sequences that not alone but in combination with cDDP, these
drugs may cause evident aldosterone resistance. Since(AGAACAnnnTGTTCT) contain a cDDP-sensitive ad-
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